Notice of AGM and Posting of 2019 Annual Report

RNS Number : 0962A

C4X Discovery Holdings PLC

17 January 2020

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Notice of Annual General Meeting and Posting of 2019 Annual Report

17 January 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that the Annual General Meeting of the Company will be held on 31 January 2020, at 11:00am, at Panmure Gordon, One New Change, London.  The Annual Report and Financial Statements for the year ended 31 July 2019, has been published and sent to shareholders.

A copy of the 2019 Annual Report can be viewed on, and downloaded from, the Company's website at https://www.c4xdiscovery.com.

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
James Stearns (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com

 

END

 

 

MSCBFMBTMTTBTMM